Key result
Renal artery denervation remains the only guideline-supported interventional therapy for resistant hypertension.
Why the study?
Achieving blood pressure targets remains challenging despite available pharmacotherapies, motivating the development and evaluation of novel interventional strategies targeting autonomic and vascular regulation.
While several novel interventional strategies for resistant hypertension are under investigation, renal artery denervation remains the only device-based therapy currently supported by clinical guidelines.
Guideline-endorsed renal denervation use continues in selected resistant hypertension; leaves open the role of alternative devices pending prospective data.
Achievement of blood pressure targets in hypertensive patients is a challenge for clinicians despite the different classes of drugs currently available. For this reason, taking advantage of the technological progress, new interventional strategies have been proposed. Each of these approaches acts on autonomic and vascular regulation, critical components of hypertension pathophysiology with the aim to recalibrate aberrant sympathetic activation and vascular dysfunction. Renal artery denervation is the only modality currently supported by guideline recommendations in selected patients. Baroreflex activation therapy, and carotid body modulation, thanks to good experimental results, are under evaluation as promising strategies. Concurrently, newer modalities, such as deep brain stimulation, cardiac neuromodulation, and arteriovenous shunts, are emerging with promising early data. The present narrative review provides an overview of interventional treatments for hypertension, describing their efficacy, mechanism of action, safety, and side effects. As clinical research progresses, there is the possibility that these techniques will emerge as promising treatment options for patients with resistant hypertension in the near future.
No takes yet. Share an insight, caveat, or question.
Şener et al. (2026) conducted a review in Arterial Hypertension. Interventional treatments (e.g., renal artery denervation, baroreflex activation therapy) vs. Pharmacotherapy or sham control was evaluated. Renal artery denervation is currently the only interventional modality supported by guideline recommendations for selected patients with resistant hypertension, while other device-based therapies remain under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: